| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 14 | 2019 | 833 | 2.530 |
Why?
|
| Vancomycin | 10 | 2016 | 75 | 2.150 |
Why?
|
| Clostridium Infections | 10 | 2022 | 126 | 2.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 16 | 2023 | 940 | 1.820 |
Why?
|
| Antifungal Agents | 13 | 2020 | 122 | 1.750 |
Why?
|
| Enterocolitis, Pseudomembranous | 8 | 2019 | 52 | 1.730 |
Why?
|
| Herpes Zoster | 5 | 2019 | 25 | 1.710 |
Why?
|
| Triazoles | 10 | 2018 | 110 | 1.490 |
Why?
|
| Aminoglycosides | 7 | 2013 | 31 | 1.450 |
Why?
|
| Antiviral Agents | 10 | 2021 | 364 | 1.170 |
Why?
|
| Herpes Zoster Vaccine | 3 | 2019 | 6 | 1.140 |
Why?
|
| Invasive Fungal Infections | 5 | 2020 | 10 | 1.130 |
Why?
|
| Nitriles | 5 | 2018 | 154 | 0.940 |
Why?
|
| Immunocompromised Host | 12 | 2021 | 136 | 0.940 |
Why?
|
| Pyridines | 6 | 2018 | 302 | 0.920 |
Why?
|
| Organophosphonates | 3 | 2018 | 46 | 0.730 |
Why?
|
| Cytosine | 3 | 2018 | 121 | 0.690 |
Why?
|
| Organ Transplantation | 3 | 2019 | 295 | 0.650 |
Why?
|
| Double-Blind Method | 15 | 2023 | 1727 | 0.640 |
Why?
|
| Cytomegalovirus Infections | 5 | 2019 | 111 | 0.580 |
Why?
|
| Mycoses | 3 | 2020 | 44 | 0.540 |
Why?
|
| Peptides, Cyclic | 2 | 2016 | 40 | 0.540 |
Why?
|
| Thiazoles | 2 | 2014 | 124 | 0.520 |
Why?
|
| Adenosine Monophosphate | 3 | 2021 | 29 | 0.500 |
Why?
|
| Lipopeptides | 2 | 2016 | 20 | 0.500 |
Why?
|
| Valine | 1 | 2016 | 46 | 0.490 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 21 | 0.490 |
Why?
|
| Alanine | 3 | 2021 | 82 | 0.490 |
Why?
|
| Acyclovir | 1 | 2016 | 35 | 0.490 |
Why?
|
| Drugs, Investigational | 1 | 2016 | 36 | 0.480 |
Why?
|
| Adult | 43 | 2022 | 27849 | 0.480 |
Why?
|
| Middle Aged | 39 | 2020 | 27535 | 0.450 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 175 | 0.450 |
Why?
|
| Aged | 29 | 2020 | 20395 | 0.450 |
Why?
|
| Transplant Recipients | 6 | 2023 | 159 | 0.420 |
Why?
|
| Male | 50 | 2020 | 44353 | 0.410 |
Why?
|
| Humans | 68 | 2024 | 93130 | 0.400 |
Why?
|
| Invasive Pulmonary Aspergillosis | 3 | 2018 | 8 | 0.390 |
Why?
|
| Daptomycin | 1 | 2013 | 3 | 0.390 |
Why?
|
| Minocycline | 1 | 2013 | 14 | 0.390 |
Why?
|
| Edetic Acid | 1 | 2013 | 40 | 0.380 |
Why?
|
| Treatment Outcome | 21 | 2020 | 9070 | 0.380 |
Why?
|
| Female | 42 | 2020 | 48540 | 0.370 |
Why?
|
| Biofilms | 1 | 2013 | 50 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1054 | 0.360 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 85 | 0.350 |
Why?
|
| Actinomycetales | 1 | 2011 | 5 | 0.350 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2011 | 16 | 0.350 |
Why?
|
| Neoplasms | 2 | 2019 | 3168 | 0.340 |
Why?
|
| Administration, Oral | 6 | 2018 | 655 | 0.330 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2020 | 24 | 0.330 |
Why?
|
| HIV Infections | 4 | 2013 | 952 | 0.320 |
Why?
|
| Ethanol | 1 | 2013 | 273 | 0.320 |
Why?
|
| Aged, 80 and over | 10 | 2018 | 7039 | 0.320 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 256 | 0.300 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 195 | 0.300 |
Why?
|
| Respiratory Tract Infections | 2 | 2020 | 109 | 0.290 |
Why?
|
| Hematologic Neoplasms | 3 | 2020 | 372 | 0.280 |
Why?
|
| Administration, Intravenous | 5 | 2020 | 63 | 0.280 |
Why?
|
| Mucormycosis | 4 | 2018 | 15 | 0.260 |
Why?
|
| Young Adult | 9 | 2018 | 6922 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 916 | 0.240 |
Why?
|
| Acetates | 2 | 2017 | 57 | 0.240 |
Why?
|
| Diarrhea | 4 | 2015 | 176 | 0.230 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 338 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 333 | 0.220 |
Why?
|
| Adolescent | 13 | 2018 | 9550 | 0.220 |
Why?
|
| Quinazolines | 2 | 2017 | 211 | 0.220 |
Why?
|
| Legionellosis | 1 | 2024 | 6 | 0.220 |
Why?
|
| Legionella | 1 | 2024 | 16 | 0.220 |
Why?
|
| Vaccination | 2 | 2019 | 303 | 0.210 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 37 | 0.210 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 8 | 0.200 |
Why?
|
| Transplantation, Homologous | 4 | 2016 | 1014 | 0.200 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 44 | 0.200 |
Why?
|
| Cytomegalovirus | 3 | 2018 | 71 | 0.190 |
Why?
|
| Vaccines, Inactivated | 2 | 2019 | 32 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 202 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 165 | 0.180 |
Why?
|
| Mycobacterium chelonae | 1 | 2021 | 4 | 0.170 |
Why?
|
| Reaction Time | 2 | 1999 | 316 | 0.170 |
Why?
|
| DNA, Viral | 3 | 2017 | 234 | 0.170 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 25 | 0.170 |
Why?
|
| Coronary Disease | 2 | 1995 | 221 | 0.170 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 20 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 283 | 0.160 |
Why?
|
| Drug Resistance, Viral | 2 | 2019 | 37 | 0.160 |
Why?
|
| Cardiomyopathies | 2 | 2017 | 300 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 874 | 0.150 |
Why?
|
| Anti-HIV Agents | 2 | 1999 | 193 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2022 | 80 | 0.150 |
Why?
|
| Injection Site Reaction | 1 | 2019 | 2 | 0.150 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1910 | 0.150 |
Why?
|
| Recurrence | 3 | 2017 | 1188 | 0.150 |
Why?
|
| Bordetella Infections | 1 | 2018 | 5 | 0.140 |
Why?
|
| Aminoimidazole Carboxamide | 2 | 1995 | 8 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2020 | 178 | 0.140 |
Why?
|
| Drug Therapy, Combination | 5 | 2011 | 753 | 0.140 |
Why?
|
| Ribonucleosides | 2 | 1995 | 22 | 0.140 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 208 | 0.140 |
Why?
|
| Neutrophils | 4 | 1999 | 324 | 0.140 |
Why?
|
| Psychomotor Performance | 3 | 2000 | 497 | 0.140 |
Why?
|
| Coinfection | 1 | 2018 | 67 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 156 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2018 | 1518 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 97 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2017 | 93 | 0.130 |
Why?
|
| Neutropenia | 1 | 2018 | 209 | 0.130 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 15 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2301 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2012 | 144 | 0.130 |
Why?
|
| Investigational New Drug Application | 1 | 2016 | 2 | 0.120 |
Why?
|
| Foscarnet | 1 | 2016 | 9 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 357 | 0.120 |
Why?
|
| Zygomycosis | 2 | 2007 | 3 | 0.120 |
Why?
|
| Myocarditis | 1 | 2017 | 59 | 0.120 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 33 | 0.120 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 47 | 0.120 |
Why?
|
| Health Behavior | 1 | 2017 | 182 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2016 | 77 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 83 | 0.120 |
Why?
|
| Mannans | 1 | 2015 | 5 | 0.110 |
Why?
|
| beta-Glucans | 1 | 2015 | 7 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 95 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2019 | 618 | 0.110 |
Why?
|
| Cognition | 1 | 1999 | 625 | 0.110 |
Why?
|
| Candida | 2 | 2012 | 20 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 365 | 0.100 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1995 | 180 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 984 | 0.100 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 57 | 0.100 |
Why?
|
| Vaccines, Attenuated | 1 | 2013 | 52 | 0.100 |
Why?
|
| Fibrinolytic Agents | 1 | 1995 | 238 | 0.100 |
Why?
|
| Aspergillus | 3 | 2018 | 9 | 0.100 |
Why?
|
| Histoplasmosis | 1 | 2013 | 27 | 0.100 |
Why?
|
| Clinical Medicine | 1 | 2013 | 26 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 78 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2013 | 199 | 0.090 |
Why?
|
| Amphotericin B | 2 | 2009 | 33 | 0.090 |
Why?
|
| Enterococcus | 1 | 2012 | 34 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2015 | 4546 | 0.090 |
Why?
|
| HIV-1 | 3 | 1998 | 173 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 827 | 0.090 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2011 | 98 | 0.080 |
Why?
|
| Microbiota | 1 | 2015 | 431 | 0.080 |
Why?
|
| Cross Infection | 1 | 2011 | 149 | 0.080 |
Why?
|
| Mucor | 1 | 2009 | 3 | 0.080 |
Why?
|
| Fungi | 3 | 2018 | 67 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2021 | 10128 | 0.070 |
Why?
|
| Multiple Myeloma | 2 | 2018 | 336 | 0.070 |
Why?
|
| Thromboxane-A Synthase | 1 | 1989 | 4 | 0.070 |
Why?
|
| Glycosides | 1 | 2008 | 12 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1989 | 96 | 0.070 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1989 | 56 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 147 | 0.070 |
Why?
|
| Arachidonic Acids | 1 | 1988 | 36 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1999 | 67 | 0.070 |
Why?
|
| Substance-Related Disorders | 2 | 2003 | 440 | 0.070 |
Why?
|
| AIDS Dementia Complex | 2 | 1998 | 7 | 0.060 |
Why?
|
| Aspergillosis | 2 | 2018 | 39 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 825 | 0.060 |
Why?
|
| Feces | 3 | 2014 | 360 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2019 | 291 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2007 | 234 | 0.060 |
Why?
|
| Child | 6 | 2022 | 7273 | 0.060 |
Why?
|
| Fungemia | 1 | 2005 | 15 | 0.060 |
Why?
|
| Candidiasis | 1 | 2005 | 39 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 878 | 0.060 |
Why?
|
| United States | 4 | 2022 | 7581 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2005 | 136 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 3 | 1999 | 73 | 0.050 |
Why?
|
| Incidence | 3 | 2014 | 1697 | 0.050 |
Why?
|
| Hospitalization | 2 | 2020 | 924 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2004 | 49 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2007 | 382 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 873 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 1908 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 89 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2024 | 292 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 101 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 9 | 0.050 |
Why?
|
| Voriconazole | 2 | 2018 | 19 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 32 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2023 | 19 | 0.050 |
Why?
|
| Patient Isolation | 1 | 2003 | 14 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 111 | 0.050 |
Why?
|
| Disaster Planning | 1 | 2003 | 24 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2023 | 103 | 0.050 |
Why?
|
| Zidovudine | 2 | 1999 | 12 | 0.050 |
Why?
|
| HIV Seropositivity | 2 | 2000 | 49 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 981 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 59 | 0.040 |
Why?
|
| Platelet Aggregation | 2 | 1994 | 40 | 0.040 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2001 | 8 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 465 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2001 | 24 | 0.040 |
Why?
|
| Secondary Prevention | 2 | 2013 | 173 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1999 | 158 | 0.040 |
Why?
|
| Child, Preschool | 4 | 2013 | 3781 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2001 | 72 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2020 | 38 | 0.040 |
Why?
|
| Verbal Learning | 1 | 2000 | 30 | 0.040 |
Why?
|
| Respiratory System | 1 | 2020 | 117 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 67 | 0.040 |
Why?
|
| Zalcitabine | 1 | 1999 | 1 | 0.040 |
Why?
|
| Didanosine | 1 | 1999 | 1 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 67 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 1999 | 18 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2024 | 367 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1519 | 0.040 |
Why?
|
| Biomarkers | 2 | 2016 | 1905 | 0.040 |
Why?
|
| Infant | 3 | 2016 | 3156 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 300 | 0.040 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 6 | 0.040 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 38 | 0.040 |
Why?
|
| Phagocytes | 1 | 1998 | 15 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2018 | 110 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 709 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 212 | 0.040 |
Why?
|
| Mucorales | 1 | 2018 | 2 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 1998 | 502 | 0.030 |
Why?
|
| Choice Behavior | 1 | 1999 | 159 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2018 | 71 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 232 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1999 | 500 | 0.030 |
Why?
|
| Blood Platelets | 2 | 1989 | 149 | 0.030 |
Why?
|
| Dogs | 2 | 1995 | 632 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2019 | 219 | 0.030 |
Why?
|
| Allografts | 1 | 2018 | 205 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1172 | 0.030 |
Why?
|
| Memory Disorders | 1 | 1997 | 72 | 0.030 |
Why?
|
| Social Isolation | 1 | 2017 | 71 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 359 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2000 | 242 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 8 | 0.030 |
Why?
|
| Pilot Projects | 1 | 1999 | 913 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2016 | 25 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2016 | 16 | 0.030 |
Why?
|
| Parturition | 1 | 2016 | 21 | 0.030 |
Why?
|
| Lymphoma | 1 | 2018 | 247 | 0.030 |
Why?
|
| Femoral Vein | 1 | 2016 | 42 | 0.030 |
Why?
|
| Prognosis | 2 | 2015 | 3890 | 0.030 |
Why?
|
| Immunization | 1 | 2016 | 154 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2016 | 94 | 0.030 |
Why?
|
| Leukemia | 1 | 2018 | 300 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1171 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2016 | 2427 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5900 | 0.030 |
Why?
|
| Enema | 1 | 2015 | 35 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 154 | 0.030 |
Why?
|
| Galactose | 1 | 2015 | 27 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 373 | 0.030 |
Why?
|
| Mothers | 1 | 2016 | 142 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 995 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1925 | 0.030 |
Why?
|
| 5,8,11,14-Eicosatetraynoic Acid | 1 | 1994 | 2 | 0.030 |
Why?
|
| Placenta | 1 | 2016 | 188 | 0.030 |
Why?
|
| Catalase | 1 | 1994 | 46 | 0.030 |
Why?
|
| Peroxidase | 1 | 1994 | 54 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1945 | 0.030 |
Why?
|
| Animals | 5 | 2016 | 27968 | 0.030 |
Why?
|
| Perfusion | 1 | 1995 | 260 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 379 | 0.030 |
Why?
|
| Apoptosis | 2 | 1999 | 1719 | 0.030 |
Why?
|
| Mental Recall | 1 | 1995 | 172 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 1999 | 1849 | 0.030 |
Why?
|
| Attention | 1 | 1998 | 410 | 0.030 |
Why?
|
| Luminescent Measurements | 3 | 1999 | 64 | 0.020 |
Why?
|
| Arachidonic Acid | 2 | 1994 | 62 | 0.020 |
Why?
|
| Free Radicals | 2 | 1994 | 69 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2012 | 21 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 194 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 81 | 0.020 |
Why?
|
| Adenosine | 1 | 1994 | 274 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 888 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 80 | 0.020 |
Why?
|
| Neuropsychological Tests | 3 | 1998 | 541 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1240 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 3450 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2787 | 0.020 |
Why?
|
| Phenylacetates | 1 | 1989 | 3 | 0.020 |
Why?
|
| Rats, Inbred SHR | 1 | 1989 | 33 | 0.020 |
Why?
|
| Hydralazine | 1 | 1989 | 21 | 0.020 |
Why?
|
| Pregnancy | 1 | 2016 | 3128 | 0.020 |
Why?
|
| Respiratory Burst | 2 | 1999 | 19 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1989 | 27 | 0.020 |
Why?
|
| Indomethacin | 1 | 1989 | 58 | 0.020 |
Why?
|
| Benzazepines | 1 | 1989 | 64 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1989 | 313 | 0.020 |
Why?
|
| Eicosanoic Acids | 1 | 1988 | 2 | 0.020 |
Why?
|
| Lipoxygenase | 1 | 1988 | 9 | 0.020 |
Why?
|
| SRS-A | 1 | 1988 | 27 | 0.020 |
Why?
|
| Cell Communication | 1 | 1989 | 216 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 1988 | 53 | 0.020 |
Why?
|
| Superoxides | 1 | 1988 | 75 | 0.020 |
Why?
|
| Serotonin | 1 | 1988 | 209 | 0.020 |
Why?
|
| Sulfonamides | 1 | 1989 | 331 | 0.020 |
Why?
|
| Echinocandins | 1 | 2005 | 5 | 0.010 |
Why?
|
| Internationality | 1 | 2005 | 78 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1989 | 887 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 205 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 206 | 0.010 |
Why?
|
| Kidney | 1 | 1989 | 1093 | 0.010 |
Why?
|
| Oxygen | 1 | 1988 | 749 | 0.010 |
Why?
|
| Rats | 1 | 1989 | 4028 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2004 | 289 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 1463 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 367 | 0.010 |
Why?
|
| Filgrastim | 1 | 1999 | 56 | 0.010 |
Why?
|
| Problem Solving | 1 | 1998 | 55 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1998 | 139 | 0.010 |
Why?
|
| Acridine Orange | 1 | 1996 | 2 | 0.010 |
Why?
|
| Ethidium | 1 | 1996 | 13 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 42 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1996 | 121 | 0.010 |
Why?
|
| Cell Size | 1 | 1996 | 71 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 429 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1995 | 12 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1996 | 435 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1995 | 66 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1996 | 710 | 0.010 |
Why?
|
| Adenosine Kinase | 1 | 1994 | 1 | 0.010 |
Why?
|
| Tubercidin | 1 | 1994 | 1 | 0.010 |
Why?
|
| Blood Physiological Phenomena | 1 | 1994 | 9 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1994 | 6 | 0.010 |
Why?
|
| Scintillation Counting | 1 | 1994 | 5 | 0.010 |
Why?
|
| Dipyridamole | 1 | 1994 | 12 | 0.010 |
Why?
|
| Coronary Thrombosis | 1 | 1994 | 15 | 0.010 |
Why?
|
| Theophylline | 1 | 1994 | 34 | 0.010 |
Why?
|
| Plasma | 1 | 1994 | 48 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1994 | 26 | 0.010 |
Why?
|
| Cell Survival | 1 | 1996 | 1002 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 183 | 0.010 |
Why?
|
| Psychometrics | 1 | 1995 | 336 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1994 | 235 | 0.010 |
Why?
|
| Aspirin | 1 | 1994 | 164 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1994 | 175 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 1022 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1994 | 280 | 0.010 |
Why?
|
| Cohort Studies | 1 | 1998 | 3044 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1994 | 467 | 0.010 |
Why?
|
| DNA | 1 | 1996 | 1260 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1995 | 2705 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1994 | 2479 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1994 | 1769 | 0.000 |
Why?
|